Phil Ball, PhD, is a biopharmaceutical executive and board member with experience spanning venture-backed startups to multinational pharmaceutical companies. He has helped build and scale organizations from formation through acquisition, leading strategic transactions across in-licensing, out-licensing, and M&A. He is Chief Business Officer and a founding team member of Tolerance Bio, where he has helped build the company from inception - shaping corporate strategy, spearheading fundraising efforts, and developing a robust IP and R&D pipeline through licensing and strategic collaborations. At Provention Bio, Phil led licensing initiatives, managed major global alliances, and supported commercialization planning. He served as a senior business development leader through the company’s $3 billion acquisition by Sanofi. At Allergan (later acquired by AbbVie), he played a central role in the buildout of the company’s biologics portfolio through strategic business development and organic growth initiatives, advancing programs from preclinical development through launch. He later led value and access policy strategy and managed high-profile strategic partnerships and trade association initiatives. Phil began his career as a founding team member of Eden Biodesign (acquired by Watson Pharmaceuticals) and holds a PhD in Biochemistry from the University of Liverpool.